Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

The 10-second video shows the rapper playing with a football and an ending tag, “See you at the game,” with the Pfizer logo. Additional teasers will be posted Saturday and Sunday mornings ...

Ahead of next Tuesday's earnings release, Pfizer seems undervalued based on current price of $26.55 & valuation of $150bn. But is it madness to expect upside? Quite possibly it is. My DCF analysis ...

Activist Starboard Value has decided not to pursue a proxy battle with Pfizer. Starboard built a $1 billion stake in Pfizer in October and reportedly planned to push for changes. Get two weeks of ...

Recently, Pfizer found itself in the agency's crosshairs thanks to one of its M&A plays. Now, Pfizer—which purchased neuroscience specialist Biohaven for $11.6 billion in 2022—is committing ...

Activist Starboard Value did not nominate any directors to Pfizer’s (PFE) board ahead of a January 25 deadline for the company’s annual meeting in April, Damian Garde and Crystal Tse of ...

Pfizer acquired Biohaven for $11.6bn in October 2022 based on a strong sales forecast for Nurtec ODT. Image credit: Shutterstock/Molly Woodward. Pfizer has agreed to pay $59.7m to resolve illegal ...

Pfizer PFE-0.43%decrease; red down pointing triangle will pay $60 million to settle allegations that one of its subsidiaries incentivized healthcare providers to prescribe one of its drugs ...

U.S. drugmaker Pfizer PFE.N is going “all in” to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the JPMorgan ...

NEW YORK, Jan 24 (Reuters) - Pfizer (PFE.N), opens new tab will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares closed yesterday at $26.01. According to ...